Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive…
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
September 11, 2025 09:00 ET Â | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows…
